Background: Common risk factors for coronary heart disease (CHD) and abdominal aortic aneurysm (AAA) are mainly male gender, past or current smoking and older age. But little is known about AAA prevalence in this welldefined population. The aim of this prospective study was to evaluate the prevalence of AAA in patients presenting with an acute coronary syndrome and coronary stenosis ≥ 50% at coronarography.
Results: Among 10287 subjects in Europe, 1011 were included in France. The mean age is 65 yrs (males 55%). ABI≤0.9 was found in 12. 2% (95%CI [10.1; 14.2] ). Mean LDL-cholesterol was 1.29 g/L. Results for RF association (Logistic regression) are shown in table 1.
Table.
Conclusion: In the Pandora study, the prevalence of asymptomatic PAD among subjects with moderate CV risk in France is 12.2%, strongly related to smoking and low physical activity. In patients with moderate CV risk, detection of asymptomatic PAD and management of modifiable RF such as smoking and physical activity could improve the overall CV risk. PANDORA Study was sponsored by AstraZeneca.
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Ten-year risk of cancer mortality according to lipid levels and use of lipid-lowering drugs in the French general population Emilie Bérard (1), Vanina Bongard (2), Philippe Amouyel (3), Dominique Arveiler (4), Jean Dallongeville (3), Aline Wagner (5), Dominique Cottel (6), Bernadette Haas (5), Jean-Bernard Ruidavets (2), Jean Ferrières (7 Purpose: The beneficial effect of lipid-lowering drugs on cardiovascular mortality is well established, but long term safety data remain scarce. The aim of this study was to assess 10-year risk of cancer mortality according to blood lipid levels and lipid-lowering drug exposure, in the French general population.
Methods:
Our analysis was based on the Third French MONICA Crosssectional survey on cardiovascular risk factors (1995) (1996) . Participants aged 35-64 years were randomly recruited from French polling lists. Subjects with a history of cancer at baseline were excluded from the analysis. Vital status and cause of mortality were obtained 10 years after inclusion.
Results: There were 3262 participants and 177 deaths were recorded (78 due to cancer). The sample was mainly composed of subjects in primary cardiovascular prevention (96%) and comprised 64% of normolipidemic, 25% of untreated dyslipidemic (total cholesterol ≥ 6.5 mmol/L or triglycerides ≥ 3.5 mmol/L) and 11% of dyslipidemic subjects treated with a lipid-lowering drug (4% statin, 6% fibrate). After adjustment for centre, age, smoking, gamma- 
